JosephChaoMD

Oncology • Duarte, CA

Gastrointestinal Cancer

Associate Clinical Professor

Join to view full profile

Dr. Chao is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Chao's full profile

Already have an account?

Office
1500 E. Duarte Rd
Duarte, CA 91010
Phone+1 626-471-9200

Fax+1 626-301-8233

Summary

Dr. Joseph Chao is an oncologist in Duarte, CA and is affiliated with City of Hope's Helford Clinical Research Hospital. He received his medical degree from University of Illinois College of Medicine and has been in practice 13 years. He specializes in gastrointestinal cancers with a research focus in stomach and esophageal cancers.

Education & Training

City of Hope National Medical CenterFellowship, Hematology and Medical Oncology, 2007 - 2010
Los Angeles County-Harbor-UCLA Medical Center 1Fellowship, Hematology and Medical Oncology, 2007 - 2010
Los Angeles County-Harbor-UCLA Medical CenterResidency, Internal Medicine, 2004 - 2007
University of Illinois College of MedicineClass of 2004

Certifications & Licensure

CA State Medical License 2006 - 2025

Clinical Trials

Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer Start of enrollment: 2011 Feb 14
Completed
Phase 3
Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery Start of enrollment: 2012 Nov 01
Completed
Phase 2
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer Start of enrollment: 2014 Jun 11
Completed
Phase 1
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery Start of enrollment: 2014 Feb 01
Completed
Phase 2
RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists Start of enrollment: 2016 Jun 13
Active, not recruiting
Phase 1
A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer Start of enrollment: 2015 Oct 12
Completed
Phase 2
APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers Start of enrollment: 2017 Oct 06
Completed
Phase 2
IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer Start of enrollment: 2019 Apr 19
Completed
Phase 1, Phase 2
Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer Start of enrollment: 2022 Jan 25
Active, not recruiting
Phase 2
Roles: Contact, Principal Investigator
Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors Start of enrollment: 2021 Dec 29
Completed
Phase 1
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

670 citations
Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
Jaffer A Ajani, Thomas A D'Amico, David J Bentrem, Joseph Chao, David Cooke
Journal of the National Comprehensive Cancer Network. 2022-02-01
17 citations
FGFR2‐Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape
Samuel J. Klempner, Russell Madison, Vivek Pujara, Jeffrey S. Ross, Vincent A. Miller
The Oncologist. 2019-06-27
129 citations
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junc...
Kohei Shitara, Florian Lordick, Yung-Jue Bang, Peter Enzinger, David Ilson
Lancet. 2023-05-20

Lectures

KRAS amplification and mutation as independent events in gastroesophageal adenocarcinomas (GEA).
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Pembro for Gastric Cancers: High Microsatellite Instability May Be Key to Good ResponsesApril 6th, 2021
Bringing Personalized Medicine to Precision Medicine in Gastroesophageal CancerFebruary 5th, 2020
City of Hope Scientists Are Using Combination Immunotherapy to Treat Advanced CancersApril 8th, 2019
Join now to see all

Committees

Gastroesophageal Medical Oncology Co-Chair, Via Oncology Pathways Disease Committee 2017 - Present
Panel Member, NCCN Gastric Cancer Guidelines 2014 - Present
Panel Member, NCCN Esophageal and Esophagogastric Junction Cancers 2014 - Present